An experimental treatment for sickle cell disease and beta thalassemia that aims to deliver genetic medicines directly to bone marrow cells.
marrowtx.comLinkedInWatertown, MassachusettsBiotech20 employees
4 sources
The page's company is not the record's
The source announces a $5 billion Series C for Isomorphic Labs, not Marrow Therapeutics. Therefore no round fields can be attributed to Marrow Therapeutics.
15 sources · checked 1 time, last 2d ago
The company’s release announces one combined financing split into a $53 million Series A and a $120 million Series B; the release is preferred over Axios’s abbreviated $m formatting.
| Round | Amount | Announced | Lead | Buzz |
|---|---|---|---|---|
| Series B | $120M | 2026-11-17 | OrbiMed | 1 person on X · 4 outlets. #110 in Trending |
4 sources [ CONTRADICTED ] read against 4 sources The page's company is not the record's The source announces a $5 billion Series C for Isomorphic Labs, not Marrow Therapeutics. Therefore no round fields can be attributed to Marrow Therapeutics. | ||||
1 person on 4 outlets
4 people on
Marrow Therapeutics is developing injectable genetic medicines that target bone-marrow cells to treat people with sickle cell disease, beta thalassemia and other severe blood disorders.
Marrow matters because current genetic treatments for sickle cell disease and beta thalassemia require collecting and modifying a patient's cells outside the body, chemotherapy conditioning and reinfusion, while Marrow's in-vivo approach is designed to deliver payloads directly to bone-marrow cells through a simpler injection. Its $173 million Series A/B backing funds preclinical MAR-101 and manufacturing as the company tries to make a safer, more scalable and globally accessible alternative, but the candidate has not yet been tested in humans.
Checked against 10 sources 2d ago
| Series A Series A and B funding | $173M $173M financing total | 2026-11-17 | OrbiMed, Scion Life Sciences, venBio | 4 people on X · 10 outlets. #50 in Trending |
15 sources · checked 1 time, last 2d ago [ VERIFIED ] read against 4 of 15 sources The company’s release announces one combined financing split into a $53 million Series A and a $120 million Series B; the release is preferred over Axios’s abbreviated $m formatting. [ BUILT WITH ]·[ SEARCH ]found by the research agent·[ SCRAPE ]15 pages read: marrowtx.com, businesswire.com, axios.com·[ JSON ]round read into a schema, with the sentence that states it·[ VERIFY ]confirmedchecked against 4 of 15 sources·[ BRANDING ]logo and colour from the homepage·[ ]posts from 4 people, found with Firecrawl search·[ AGENT ]company research by the Firecrawl agent | ||||
Found on X with Firecrawl search